Loading companies…
ET
Encoded Therapeutics Inc.
United States · Biotech
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
Selective gene regulation for neurological disease
Encoded engineers gene therapies to target specific cell types and regulate disease-relevant genes. Its lead candidate, ETX101, is designed to increase SCN1A expression in inhibitory neurons, addressing the underlying gene insufficiency associated with SCN1A-positive Dravet syndrome rather than only managing seizures symptom by symptom.
Clinical-stage development
ETX101 is being studied as a potential one-time treatment for infants, children and adolescents with Dravet syndrome. The company reported that the candidate had entered pivotal development in 2026, following Phase 1/2 trials; its broader pipeline applies the vector-engineering platform to additional neurological disorders. These are investigational therapies, not marketed treatments.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series F | $275M | GV — LeadARCH Venture Partners — ParticipantBraidwell LP — ParticipantFarallon Capital Management — ParticipantIllumina Ventures — ParticipantInvus — ParticipantJanus Henderson Investors — ParticipantMatrix Capital Management — ParticipantNolan Capital — ParticipantRTW Investments — ParticipantSoftBank Vision Fund 2 — ParticipantVenrock — Participant |
Investors
GVLed Series FARCH Venture PartnersJoined Series FBraidwell LPJoined Series FFarallon Capital ManagementJoined Series FIllumina VenturesJoined Series FInvusJoined Series FJanus Henderson InvestorsJoined Series FMatrix Capital ManagementJoined Series FNolan CapitalJoined Series FRTW InvestmentsJoined Series FSoftBank Vision Fund 2Joined Series FVenrockJoined Series FCoverage
Sep 9, 2026Encoded Therapeutics Inc. · Series FSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed